Christopher Yea - Nov 21, 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Development Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Nov 21, 2022
Transactions value $
-$6,196
Form type
4
Date filed
11/21/2022, 03:21 PM
Previous filing
Aug 19, 2022
Next filing
May 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +1.77K +5.28% 35.4K Nov 17, 2022 Direct F1
transaction KALV Common Stock Sale -$6.2K -1.14K -3.22% $5.44 34.2K Nov 18, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -1.77K -6.67% $0.00 24.8K Nov 17, 2022 Common Stock 1.77K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.